Sita-Met Xr Tablets 50/1000Mg (1 Box = 2 Strips) (1 Strip = 7 Tablets)
By increasing and prolonging active incretin levels, Sitagliptin increases insulin release and decreases glucagon...
By increasing and prolonging active incretin levels, Sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. It is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.
Purpose
Diabetes
Ingredients
Sitagliptin, Metformin
Warnings
Since impaired hepatic function has been associated with some cases of lactic acidosis, Sitagliptin+Metformin HCl is advised to generally be avoided in patients with clinical or laboratory evidence of hepatic disease.
Patient receiving Sitagliptin+Metformin HCl in combination with a sulphonylurea or with insulin may be at risk for hypoglycemia. Therefore, a reduction in the dose of the sulphonylurea or insulin may be necessary.
After initiation of Sitagliptin, patients is advised to be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Sitagliptin is advised to promptly be discontinued and appropriate management is advised to be initiated.
Side Effects
Common: nausea.Uncommon: somnolence, diarrhea, upper abdominal pain and blood glucose decreased.
Storage Instructions
Store this medicine at room temperature, away from direct light and heat.
| Brand | CCL |
| Status | Active |
Related Products
